Rheumatology

Your Article Summary

See Latest Articles

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
New England Journal of Medicine, 09/14/07

Jaccard, A., et al. - High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation has been reported to provide higher response rates and better overall survival than standard chemotherapy in immunoglobulin-light-chain (AL) amyloidosis, but these two strategies have not been compared in a randomized study...Conclusions: The outcome of treatment of AL amyloidosis with high-dose melphalan plus autologous stem-cell rescue was not superior to the outcome with standard-dose melphalan plus dexamethasone

Today in Amyloidosis...keeping you current

Receive free subspecialty "5-minute updates" via email

Left Ventricular Ejection Time on Echocardiography Predicts Long-Term Mortality in Light Chain Amyloidosis
Journal of the American Society of Echocardiography, 11/04/09

Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature
Amyloid The Journal of Protein Folding Disorders, 11/18/09

Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome
Hypertension Research, 11/12/09

See All of Amyloidosis

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09

See All of Clinical Pharmacology